HLB Therapeutics Co.,Ltd.
115450
Ранг среди акций
#18346
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Цена акции
$2.08
Рыночная капитализация
$195.63M
Изменение (1 день)
10.77%
Изменение (1 год)
1.42%
Страна
KR
Торговля HLB Therapeutics Co.,Ltd. (115450)
Категория
Healthcare
Коэффициент P/S для HLB Therapeutics Co.,Ltd. (115450)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций HLB Therapeutics Co.,Ltd., текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для HLB Therapeutics Co.,Ltd. с 2026 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| Недостаточно данных для указанных дат. | ||
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
